Crossmark

Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria

Crossref DOI link: https://doi.org/10.1186/s12879-023-08699-7

Published Online: 2023-10-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bell, Griffin J

Gyaase, Stephaney

Goel, Varun

Adu, Bright

Mensah, Benedicta

Essone, Paulin

Dosoo, David

Osei, Musah

Niare, Karamoko

Wiru, Kenneth

Brandt, Katerina

Emch, Michael

Ghansah, Anita

Asante, Kwaku Poku

Mvalo, Tisungane

Agnandji, Selidji Todagbe

Juliano, Jonathan J

Bailey, Jeffrey A
Funding

Funding for this research was provided by:

National Institutes of Health (1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01, 1R01AI137410-01)
License Information

Text and Data Mining valid from 2023-10-23

Version of Record valid from 2023-10-23
More Information

Article History

Received: 30 May 2023

Accepted: 11 October 2023

First Online: 23 October 2023

Declarations

:

: This is a secondary analysis of phase III clinical trial data (NCT00866619). The trial protocol was approved by the ethical review board at each study center and partner institution and by the national regulatory authority in each country and the trial was undertaken in accordance with the provisions of the Good Clinical Practice Guidelines.

: Not Applicable.

: The authors declare no conflicts of interest. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation.

Document is current

Any future updates will be listed below